Tilray (TLRY) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

TLRY · Stock Price

USD 5.66+1.36 (+31.63%)

Market Cap: $662.0M

Historical price data

Market Cap: $662.0MPipeline: 8 drugs (1 Phase 3)Patents: 1Founded: 2013Employees: 1000-5000HQ: Leamington, Canada

Sector Ranking#202 in Small Molecule Drugs

Overview

Tilray's mission is to be the world's leading cannabis-focused consumer branded goods and pharmaceutical company. Its key achievements include establishing one of the largest global footprints in cannabis cultivation and distribution, successfully merging with Aphria to create an industry leader, and building a clinical pipeline targeting serious conditions like glioblastoma and epilepsy. The company's strategy is to drive growth through its diversified portfolio—spanning cannabis, beverage alcohol, and wellness products—while investing in high-value pharmaceutical R&D to unlock long-term value from cannabinoid science.

OncologyNeurologyInflammatory Conditions

Technology Platform

A vertically integrated GMP agricultural and manufacturing platform for cannabis, encompassing advanced cultivation, proprietary genetics, multiple extraction methods, and pharmaceutical-grade formulation capabilities to supply both consumer products and clinical-stage drug candidates.

Pipeline

8

8 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Cannabidiol (CBD) Oil Capsules + Sunflower Lecithin Oil in C...	Generalized Anxiety Disorder	Phase 3
TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg) + TN-C200M2 ...	HIV Infections	Phase 2
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low...	Posttraumatic Stress Disorder	Phase 2
TN-TC11G + Temozolomide Oral Product	Glioblastoma	Phase 1/2
Cannabidiol + Placebos	Alcohol Use Disorder	Phase 1/2

Opportunities

The global expansion of legal cannabis markets, particularly in Europe and potentially the U.S., presents a massive growth runway for Tilray's CPG operations.

Success in its clinical pipeline, especially in glioblastoma or epilepsy, could unlock a high-margin, IP-protected pharmaceutical business and dramatically revalue the company.

Risk Factors

The company faces significant regulatory uncertainty across its core markets, commodity price pressure in the cannabis sector, and the inherent high failure risk of clinical-stage drug development.

Integration of acquisitions and achieving sustained profitability remain key execution challenges.

Competitive Landscape

Tilray competes with large Canadian LPs and U.S. MSOs in the cannabis CPG space, where scale and cost matter. In biotech, it faces GW/Jazz Pharmaceuticals and other cannabinoid R&D firms, differentiating itself through vertical integration and control of its pharmaceutical-grade supply chain.